Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2013

Imbruvica(Ibrutinib)AbbVie Inc. logoABBV

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AbbVie Inc.

$2.27B

Medicare cost, 2024

Medicare drug plans spent $2.3 billion on Imbruvica (ibrutinib) in 2024, for 146,351 prescriptions and refills filled by 15,343 patients. It ranks 20th among all drugs by Medicare drug plan spending. At about $15,478 per prescription it is a high-cost drug. California accounts for the most spending ($205.8 million, 9% of the total).

Medicare cost, 2024

$2.27B

-4.4% from 2023

Prescriptions

146K

$15,477.88 per claim

Patients

15K

8,828 prescribers

Total spending, 2024

$2.27B

$147,628.95 per patient

Questions and answers

How much does Medicare spend on Imbruvica?

Medicare prescription drug plans paid $2.27B for Imbruvica in 2024, for 146,351 prescriptions and refills to 15,343 patients (down 4.4% from 2023). The average cost per claim was $15,477.88.

Which state spends the most on Imbruvica?

California had the highest Medicare cost for Imbruvica in 2024: $205.8M for 13,081 claims, followed by New York ($181.0M).

Who prescribes Imbruvica the most?

Josie Montegaard, nurse practitioner in Boston, MA, had the highest Medicare cost for Imbruvica in 2024: 231 claims costing $3.6M.

Who makes Imbruvica?

Imbruvica is made by AbbVie Inc. (ABBV), listed in the Medicare spending data as Pharmacyclics,.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Imbruvica was $2.27B in 2024, after a high of $3.15B in 2021.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Imbruvica, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Josie Montegaard Boston, MANurse Practitioner23125$3.6M
Sami N Malek Ann Arbor, MIHematology16318$2.8M
Erin M Pettijohn Grand Rapids, MIHematology-Oncology18318$2.8M
Michael P Carroll Sacramento, CAHematology-Oncology16017$2.7M
Samer E Bibawi Richardson, TXHematology-Oncology14715$2.5M
Thomas J Kipps La Jolla, CAHematology-Oncology15616$2.5M
Rajeev Kulkarni Troy, OHHematology-Oncology15415$2.4M
Jeffrey H Margolis Madison Heights, MIHematology-Oncology14413$2.3M
Catherine A Flynn Boston, MANurse Practitioner15322$2.3M
Eric D Batts Holland, MIHematology-Oncology16114$2.3M
Jose M Tongol Albany, GAHematology-Oncology13914$2.3M
Antoine E Chahine Canfield, OHMedical Oncology14012$2.2M
Michael Y Choi San Diego, CAHematology-Oncology14716$2.2M
Sanjaykumar J Hapani Edmond, OKMedical Oncology13916$2.2M
Tania Orzol Rochester, NYNurse Practitioner11919$2.2M
Nicholas O Iannotti Port St Lucie, FLHematology-Oncology14014$2.1M
Matthew E Adess Highland Park, ILMedical Oncology13513$2.1M
Mark E Dailey Hartford, CTMedical Oncology111Under 11$2.1M
James L Rubenstein San Francisco, CAMedical Oncology7911$2.1M
Mohammad I Khan Louisville, KYHematology-Oncology12711$2.0M
Pamela R Sinclair Rock Hill, SCMedical Oncology12311$2.0M
Joseph D Te St George, UTHematology-Oncology12311$2.0M
Robert M Zielinski Williamsville, NYHematology12413$1.9M
Hassan I Tahsildar Green Bay, WIMedical Oncology11913$1.9M
Jorge Castillo Boston, MAHematology-Oncology13423$1.9M

Prescriber data by year

YearPrescribersClaimsPatientsCost
202210,064195,58722,193$2.85B
20239,115151,92417,085$2.37B
20248,828146,35115,343$2.27B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Pharmacyclics,ABBV logoABBV146,416$2.27B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
7
RxNorm concept IDs
1442986, 1442992, 1994360, 1994362, 2000017
Application numbers
NDA205552, NDA210563, NDA217003

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube